Enzyme engineering is one of the most commercially mature areas of protein engineering, with engineered enzymes generating billions of dollars annually across the pharmaceutical, chemical, food, and detergent industries. The field was transformed by Frances Arnold's directed evolution approach, which demonstrated that enzymes could be evolved to catalyze reactions far outside their natural repertoire, including reactions with no known biological counterpart. Today, enzyme engineering combines directed evolution with computational design and machine learning to create catalysts with precisely tailored properties.
Codexis has built one of the most successful commercial enzyme engineering platforms, developing biocatalysts for pharmaceutical manufacturing that replace toxic chemical synthesis steps with cleaner enzymatic processes. Their engineered transaminase for sitagliptin production is a landmark achievement, improving efficiency while reducing waste. Novozymes, the world's largest industrial enzyme company, applies engineering to optimize enzymes for applications in laundry detergents, food processing, and biofuels. Solugen uses engineered enzymes to produce commodity chemicals from renewable feedstocks, competing directly with petrochemical processes.
The integration of AI and machine learning is accelerating enzyme engineering cycles. Companies like Cradle and Basecamp Research use protein language models and generative AI to predict beneficial mutations and design improved enzyme variants with fewer experimental iterations. High-throughput screening technologies, including droplet microfluidics and biosensor-based selections, enable the testing of millions of variants per experiment. The convergence of computational prediction and experimental throughput is making it possible to engineer enzymes for increasingly challenging applications, including carbon capture, plastic degradation, and the synthesis of complex pharmaceutical intermediates.